

Novartis India Limited

Registered Office: Sandoz House Shivsagar Estate Dr. Annie Besant Road Worli, Mumbai 400 018

India

Tel +91 22 2495 8400

Fax +91 22 2495 0221

CIN No. L24200MH1947PLC006104

Website: www.novartis.in

Email: india.investors@novartis.com

The Secretary BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001

October 11, 2017

Statement of Investor Complaints/Grievances pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 for the Quarter ended September 30, 2017

Dear Sirs,

Pursuant to Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, please find enclosed statement of investor complaints/grievances for the quarter ended September 30, 2017.

Thanking you.

Yours sincerely,

For Novartis India Limited

Trivikram Guda Company Secretary & Compliance Officer

Encl.: as above



Novartis India Limited

Registered Office: Sandoz House Shivsagar Estate Dr. Annie Besant Road Worli, Mumbai 400 018 India

Tel +91 22 2495 8400 Fax +91 22 2495 0221

CIN No. L24200MH1947PLC006104

Website: www.novartis.in

Email: india.investors@novartis.com

Name of the Company: Novartis India Limited

Scrip Code: 500672

Statement of Investor Complaints/Grievances pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 for the Quarter ended September 30, 2017

Particulars	Number of Complaints
Complaints pending as on 01.07.2017	0
Complaints received during 01.07.2017 to 30.09.2017	2
Complaints resolved during 01.07.2017 to 30.09.2017	2
Complaints pending as on 30.09.2017	0

For Novartis India Limited

Trivikram Guda

Company Secretary & Compliance Officer